Susan L Slager

List of Publications by Year
in descending order

430 papers	19,666 citations	11651 70 h-index	14759 127 g-index
432 all docs	432 docs citations	432 times ranked	24074 citing authors

#	Article	IF	Citations
1	Familial Primary Pulmonary Hypertension (Gene PPH1) Is Caused by Mutations in the Bone Morphogenetic Protein Receptorâ€“II Gene. American Journal of Human Genetics, 2000, 67, 737-744.	6.2	1,089
2	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	21.4	960
3	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3879-3884.	7.1	853
4	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
5	Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer. Journal of Clinical Oncology, 2015, 33, 304-311.	1.6	521
6	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	21.4	513
7	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
8	Genome-wide association studies identify four ER negativeâ€“specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	21.4	374
9	A Genomewide Association Study of Citalopram Response in Major Depressive Disorder. Biological Psychiatry, 2010, 67, 133-138.	1.3	289
10	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptorâ€“negative breast cancer. Nature Genetics, 2011, 43, 1210-1214.	21.4	279
11	Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 130-144.	2.1	265
12	Mutations in CHEK2 Associated with Prostate Cancer Risk. American Journal of Human Genetics, 2003, 72, 270-280.	6.2	264
13	Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. Journal of Clinical Oncology, 2013, 31, 3272-3278.	1.6	259
14	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
15	Sequence Analysis of the Serotonin Transporter and Associations with Antidepressant Response. Biological Psychiatry, 2005, 58, 374-381.	1.3	203
16	Diffuse large <scp>B</scp>â€cell lymphoma (<scp>R</scp>ichter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. British Journal of Haematology, 2013, 162, 774-782.	2.5	187
17	Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2010, 28, 4191-4198.	1.6	184
18	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. American Journal of Hematology, 2016, 91, 1096-1101.	4.1	180

#	Article	IF	Citations
19	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nature Genetics, 2013, 45, 868-876.	21.4	179
20	Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2008, 49, 49-56.	1.3	176
21	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
22	A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Human Molecular Genetics, 2012, 21, 5373-5384.	2.9	168
23	Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10â€‰211 cases and 11â€‰905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood, 2007, 109, 3479-3488.	1.4	159
24	Case-Control Studies of Genetic Markers: Power and Sample Size Approximations for Armitageâ€™s Test for Trend. Human Heredity, 2001, 52, 149-153.	0.8	154
25	Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nature Genetics, 2010, 42, 661-664.	21.4	152
26	Analysis of Association Between the Serotonin Transporter and Antidepressant Response in a Large Clinical Sample. Biological Psychiatry, 2007, 61, 734-742.	1.3	148
27	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nature Genetics, 2014, 46, 1233-1238.	21.4	147
28	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis, 2014, 35, 1012-1019.	2.8	145
29	Evidence for Genetic Linkage Between a Polymorphism in the Adenosine 2A Receptor and Panic Disorder. Neuropsychopharmacology, 2004, 29, 558-565.	5.4	144
30	Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood, 2007, 110, 4455-4463.	1.4	144
31	Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample. PLoS ONE, 2008, 3, e1872.	2.5	144
32	Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. Journal of Clinical Oncology, 2019, 37, 144-152.	1.6	142
33	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood, 2018, 132, 49-58.	1.4	130
34	Comparison of Microsatellites Versus Single-Nucleotide Polymorphisms in a Genome Linkage Screen for Prostate Cancerâ€“Susceptibility Loci. American Journal of Human Genetics, 2004, 75, 948-965.	6.2	129
35	Tumor Necrosis Factor (TNF) and Lymphotoxin-Â (LTA) Polymorphisms and Risk of Non-Hodgkin Lymphoma in the InterLymph Consortium. American Journal of Epidemiology, 2010, 171, 267-276.	3.4	128
36	Brief Report: Natural History of Individuals With Clinically Recognized Monoclonal B-Cell Lymphocytosis Compared With Patients With Rai 0 Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2009, 27, 3959-3963.	1.6	123

#	Article	IF	Citations
37	Familial predisposition and genetic risk factors for lymphoma. Blood, 2015, 126, 2265-2273.	1.4	122
38	Evidence for a susceptibility locus for panic disorder near the catechol-O-methyltransferase gene on chromosome 22. Biological Psychiatry, 2002, 51, 591-601.	1.3	118
39	Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood, 2011, 117, 1911-1916.	1.4	118
40	Evaluation of Candidate Genes in Case-Control Studies: A Statistical Method to Account for Related Subjects. American Journal of Human Genetics, 2001, 68, 1457-1462.	6.2	114
41	Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. British Journal of Haematology, 2007, 139, 255-264.	2.5	112
42	Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood, 2011, 117, 1492-1498.	1.4	110
43	Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. Cancer Research, 2011, 71, 6240-6249.	0.9	109
44	BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood, 2015, 125, 658-667.	1.4	108
45	Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer, 2010, 116, 4777-4787.	4.1	107
46	Analysis of the RNASEL Gene in Familial and Sporadic Prostate Cancer. American Journal of Human Genetics, 2002, 71, 116-123.	6.2	105
47	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	12.8	105
48	Nonâ€Hodgkin lymphoma and obesity: A pooled analysis from the InterLymph Consortium. International Journal of Cancer, 2008, 122, 2062-2070.	5.1	104
49	B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood, 2009, 113, 4188-4196.	1.4	104
50	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leukemia and Lymphoma, 2017, 58, 1630-1639.	1.3	102
51	The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. British Journal of Haematology, 2008, 141, 615-621.	2.5	101
52	19p13.1 Is a Triple-Negativeâ€“Specific Breast Cancer Susceptibility Locus. Cancer Research, 2012, 72, 1795-1803.	0.9	100
53	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. American Journal of Human Genetics, 2013, 93, 1046-1060.	6.2	98
54	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Diffuse Large B-Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 15-25.	2.1	98

#	Article	IF	Citations
55	Base resolution methylome profiling: considerations in platform selection, data preprocessing and analysis. Epigenomics, 2015, 7, 813-828.	2.1	97
56	A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. Journal of Experimental Medicine, 2010, 207, 2569-2579.	8.5	96
57	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. American Journal of Human Genetics, 2014, 95, 462-471.	6.2	96
58	Tumor Budding in Colorectal Carcinoma. American Journal of Surgical Pathology, 2015, 39, 1340-1346.	3.7	95
59	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nature Communications, 2016, 7, 10933.	12.8	94
60	GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and Suggests Shared Genetic Susceptibility with Diffuse Large B-cell Lymphoma. PLoS Genetics, 2011, 7, e1001378.	3.5	93
61	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
62	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. Journal of Clinical Oncology, 2018, 36, 1603-1610.	1.6	93
63	Impact of Ibrutinib and Idelalisib on the Pharmaceutical Cost of Treating Chronic Lymphocytic Leukemia at the Individual and Societal Levels. Journal of Oncology Practice, 2015, 11, 252-258.	2.5	92
64	Elevated Serum B-Lymphocyte Stimulator Levels in Patients With Familial Lymphoproliferative Disorders. Journal of Clinical Oncology, 2006, 24, 983-987.	1.6	85
65	The efficacy of ibrutinib in the treatment of Richter syndrome. Blood, 2015, 125, 1676-1678.	1.4	83
66	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 41-51.	2.1	82
67	A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood, 2007, 110, 3326-3333.	1.4	79
68	A comprehensive evaluation of the prognostic significance of 13q deletions in patients with Bâ€chronic lymphocytic leukaemia. British Journal of Haematology, 2010, 148, 544-550.	2.5	79
69	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
70	Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. Cancer, 2015, 121, 2883-2891.	4.1	77
71	Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 2007, 139, 398-404.	2.5	76
72	Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood, 2012, 120, 843-846.	1.4	76

#	Article	IF	Citations
73	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	6.2	76
74	Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era. Journal of Clinical Oncology, 2010, 28, 412-417.	1.6	75
75	BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 2017, 77, 2789-2799.	0.9	75
76	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature Communications, 2017, 8, 14175.	12.8	75
77	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. Nature Communications, 2020, 11, 3353.	12.8	75
78	Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer, 2009, 115, 363-372.	4.1	72
79	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Marginal Zone Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 52-65.	2.1	70
80	Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leukemia and Lymphoma, 2009, 50, 1261-1268.	1.3	69
81	<scp>H</scp>odgkin transformation of chronic lymphocytic leukemia: <scp>I</scp>ncidence, outcomes, and comparison to de novo <scp>H</scp>odgkin lymphoma. American Journal of Hematology, 2015, 90, 334-338.	4.1	69
82	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-Î°B positive feedback loop in peripheral T-cell lymphoma. Blood, 2015, 125, 3118-3127.	1.4	68
83	A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. Blood, 2012, 119, 469-475.	1.4	66
84	Relationship between coâ€morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (<scp>CLL</scp>): a prospective cohort study. British Journal of Haematology, 2017, 178, 394-402.	2.5	66
85	Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma. Clinical Cancer Research, 2013, 19, 6812-6819.	7.0	64
86	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica, 2020, 105, 765-773.	3.5	64
87	Patterns of Dietary Fluoride Supplement Use During Infancy. Journal of Public Health Dentistry, 1998, 58, 228-233.	1.2	63
88	Common occurrence of monoclonal Bâ€cell lymphocytosis among members of highâ€risk CLL families. British Journal of Haematology, 2010, 151, 152-158.	2.5	61
89	No association of germline alteration of MSR1 with prostate cancer risk. Nature Genetics, 2003, 35, 128-129.	21.4	60
90	Chronic lymphocytic leukemia in young (<= 55 years) patients: a comprehensive analysis of prognostic factors and outcomes. Haematologica, 2014, 99, 140-147.	3.5	60

#	Article	IF	Citations
91	Genetic Variation in B-Cellâ€“Activating Factor Is Associated with an Increased Risk of Developing B-Cell Nonâ€“Hodgkin Lymphoma. Cancer Research, 2009, 69, 4217-4224.	0.9	59
92	Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leukemia and Lymphoma, 2010, 51, 620-627.	1.3	59
93	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. American Journal of Human Genetics, 2016, 99, 903-911.	6.2	59
94	Association of Mu-Opioid Receptor Variants and Response to Citalopram Treatment in Major Depressive Disorder. American Journal of Psychiatry, 2010, 167, 565-573.	7.2	58
95	The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. Leukemia and Lymphoma, 2013, 54, 290-297.	1.3	58
96	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nature Communications, 2015, 6, 5751.	12.8	58
97	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. International Journal of Epidemiology, 2017, 46, 1753-1754i.	1.9	57
98	Overall and Cancer-Specific Survival of Patients With Breast, Colon, Kidney, and Lung Cancers With and Without Chronic Lymphocytic Leukemia: A SEER Population-Based Study. Journal of Clinical Oncology, 2013, 31, 930-937.	1.6	56
99	Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer Research, 2018, 78, 2747-2759.	0.9	56
100	Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma. Blood, 2019, 133, 2776-2789.	1.4	55
101	Associations of Non-Hodgkin Lymphoma (NHL) Risk With Autoimmune Conditions According to Putative NHL Loci. American Journal of Epidemiology, 2015, 181, 406-421.	3.4	54
102	Identification of recurrent truncated <scp>DDX</scp>3X mutations in chronic lymphocytic leukaemia. British Journal of Haematology, 2015, 169, 445-448.	2.5	54
103	Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 1-14.	2.1	52
104	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. Human Molecular Genetics, 2016, 25, 1663-1676.	2.9	52
105	Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: A clinic-based case-control study. Cytokine, 2012, 60, 882-889.	3.2	50
106	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	2.5	49
107	Genome linkage screen for prostate cancer susceptibility loci: Results from the Mayo Clinic familial prostate cancer study. Prostate, 2003, 57, 335-346.	2.3	48
108	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47

#	Article	IF	Citations
109	Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. Blood, 2015, 125, 492-498.	1.4	47
110	Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. Blood, 2015, 125, 992-998.	1.4	47
111	PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data. Bioinformatics, 2014, 30, 2678-2680.	4.1	43
112	Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. Prostate, 2006, 66, 173-179.	2.3	42
113	Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia and Lymphoma, 2014, 55, 2079-2084.	1.3	42
114	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leukemia and Lymphoma, 2019, 60, 2712-2719.	1.3	42
115	Personalized risk prediction for eventâ€free survival at 24 months in patients with diffuse large Bâ€cell lymphoma. American Journal of Hematology, 2016, 91, 179-184.	4.1	41
116	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics, 2015, 24, 2966-2984.	2.9	40
117	Germline Variation in Apoptosis Pathway Genes and Risk of Nonâ€“Hodgkin's Lymphoma. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2847-2858.	2.5	39
118	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	6.2	39
119	Hematologist/oncologist diseaseâ€specific expertise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Cancer, 2012, 118, 1827-1837.	4.1	38
120	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications, 2015, 6, 7539.	12.8	38
121	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	2.9	38
122	Functional and Clinical Significance of Variants Localized to 8q24 in Colon Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2492-2500.	2.5	37
123	The physicianâ€“patient relationship and quality of life: Lessons from chronic lymphocytic leukemia. Leukemia Research, 2009, 33, 263-270.	0.8	37
124	Foodâ€frequency questionnaireâ€based estimates of total antioxidant capacity and risk of nonâ€Hodgkin lymphoma. International Journal of Cancer, 2012, 131, 1158-1168.	5.1	37
125	Elevated pretreatment serum levels of interferonâ€inducible proteinâ€10 (CXCL10) predict disease relapse and prognosis in diffuse large Bâ€cell lymphoma patients. American Journal of Hematology, 2012, 87, 865-869.	4.1	37
126	Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. British Journal of Haematology, 2018, 183, 421-427.	2.5	37

#	Article	IF	Citations
127	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer Journal, 2019, 9, 73.	6.2	37
128	Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. International Journal of Molecular Epidemiology and Genetics, 2011, 2, 95-113.	0.4	37
129	Chronic lymphocytic leukaemia genetics overview. British Journal of Haematology, 2007, 139, 630-634.	2.5	36
130	Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women. Gut, 2012, 61, 1299-1305.	12.1	36
131	Germline variation in complement genes and eventâ€free survival in follicular and diffuse large Bâ€cell lymphoma. American Journal of Hematology, 2012, 87, 880-885.	4.1	36
132	trans Fatty Acid Intake Is Associated with Increased Risk and n3 Fatty Acid Intake with Reduced Risk of Non-Hodgkin Lymphoma. Journal of Nutrition, 2013, 143, 672-681.	2.9	36
133	Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. Blood Cancer Journal, 2018, 8, 97.	6.2	36
134	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Medicine, 2020, 9, 3390-3399.	2.8	36
135	A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk. International Journal of Cancer, 2012, 131, 803-812.	5.1	35
136	Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. British Journal of Haematology, 2013, 163, 326-333.	2.5	35
137	PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium. Blood, 2012, 120, 4645-4648.	1.4	34
138	Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphoma. Cancer Causes and Control, 2012, 23, 1017-1029.	1.8	34
139	RVboost: RNA-seq variants prioritization using a boosting method. Bioinformatics, 2014, 30, 3414-3416.	4.1	34
140	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Research, 2018, 78, 4086-4096.	0.9	34
141	Familial chronic lymphocytic leukemia. Current Opinion in Hematology, 2010, 17, 350-355.	2.5	33
142	Associations Between Intake of Folate and Related Micronutrients with Molecularly Defined Colorectal Cancer Risks in the Iowa Women's Health Study. Nutrition and Cancer, 2012, 64, 899-910.	2.0	33
143	Incidence of chronic lymphocytic leukemia and highâ€count monoclonal Bâ€cell lymphocytosis using the 2008 guidelines. Cancer, 2014, 120, 2000-2005.	4.1	33
144	Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leukemia and Lymphoma, 2017, 58, 1376-1383.	1.3	33

#	Article	IF	Citations
145	Cigarette Smoking and Colorectal Cancer Risk by KRAS Mutation Status Among Older Women. American Journal of Gastroenterology, 2012, 107, 782-789.	0.4	32
146	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 87-97.	2.1	32
147	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Sporadic Burkitt Lymphoma/Leukemia: The Interlymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 106-114.	2.1	32
148	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. Annals of Hematology, 2021, 100, 143-155.	1.8	32
149	Genetic Susceptibility Variants for Chronic Lymphocytic Leukemia. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1098-1102.	2.5	31
150	Medical History, Lifestyle, and Occupational Risk Factors for Hairy Cell Leukemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 115-124.	2.1	31
151	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Mantle Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 76-86.	2.1	31
152	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31
153	Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. PLoS Genetics, 2018, 14, e1007111.	3.5	30
154	CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. Cancer Immunology, Immunotherapy, 2013, 62, 1475-1484.	4.2	28
155	Impact of post-alignment processing in variant discovery from whole exome data. BMC Bioinformatics, 2016, 17, 403.	2.6	28
156	Genetic overlap between autoimmune diseases and nonâ€Hodgkin lymphoma subtypes. Genetic Epidemiology, 2019, 43, 844-863.	1.3	28
157	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia, 2021, 35, 522-533.	7.2	28
158	Lack of intrafollicular memory CD4â€‰+â€‰T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer Journal, 2021, 11, 130.	6.2	27
159	Susceptibility genes and Bâ€chronic lymphocytic leukaemia. British Journal of Haematology, 2007, 139, 762-771.	2.5	26
160	Genetic Susceptibility to Chronic Lymphocytic Leukemia. Seminars in Hematology, 2013, 50, 296-302.	3.4	26
161	Genetic polymorphisms in oxidative stressâ€related genes are associated with outcomes following treatment for aggressive Bâ€cell nonâ€Hodgkin lymphoma. American Journal of Hematology, 2014, 89, 639-645.	4.1	26
162	History of autoimmune conditions and lymphoma prognosis. Blood Cancer Journal, 2018, 8, 73.	6.2	26

#	Article	IF	Citations
163	Postmenopausal Hormone Therapy and Colorectal Cancer Risk in Relation to Somatic KRAS Mutation Status among Older Women. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 681-684.	2.5	25
164	Genome-wide Association Study Identifies HLA-DPB1 as a Significant Risk Factor for Severe Aplastic Anemia. American Journal of Human Genetics, 2020, 106, 264-271.	6.2	25
165	Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. Journal of Clinical Oncology, 2015, 33, 3930-3937.	1.6	24
166	Genome-Wide Epigenetic Studies in Human Disease: A Primer on -Omic Technologies. American Journal of Epidemiology, 2016, 183, kwv187.	3.4	23
167	<scp>CD</scp>49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 2017, 178, 99-105.	2.5	23
168	A Two-Stage Evaluation of Genetic Variation in Immune and Inflammation Genes with Risk of Non-Hodgkin Lymphoma Identifies New Susceptibility Locus in 6p21.3 Region. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1799-1806.	2.5	22
169	An analytical workflow for accurate variant discovery in highly divergent regions. BMC Genomics, 2016, 17, 703.	2.8	22
170	ChIP-seq in studying epigenetic mechanisms of disease and promoting precision medicine: progresses and future directions. Epigenomics, 2016, 8, 1239-1258.	2.1	22
171	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2020, 71, 1221-1228.	5.8	22
172	Genetic association studies in Alzheimer's disease research: challenges and opportunities. Statistics in Medicine, 2004, 23, 169-178.	1.6	21
173	Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood, 2018, 131, 2541-2551.	1.4	21
174	Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL). Leukemia, 2021, 35, 239-244.	7.2	21
175	Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium. Cancer Causes and Control, 2013, 24, 125-134.	1.8	20
176	Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multiâ€institutional study. American Journal of Hematology, 2016, 91, 687-691.	4.1	20
177	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. British Journal of Haematology, 2018, 182, 644-653.	2.5	20
178	Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance. Blood Advances, 2020, 4, 2789-2797.	5.2	20
179	The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. Blood, 2021, 138, 149-159.	1.4	20
180	Luteinizing hormone Î² polymorphism and risk of familial and sporadic prostate cancer. Prostate, 2003, 56, 30-36.	2.3	19

#	Article	IF	Citations
181	The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of gender. Annals of Epidemiology, 2012, 22, 855-862.	1.9	19
182	Skin Cancer Surveillance and Malignancies of the Skin in a Community-Dwelling Cohort of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia. Journal of Oncology Practice, 2014, 10, e1-e4.	2.5	19
183	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in nonâ€follicular indolent Bâ€cell lymphomas. American Journal of Hematology, 2019, 94, 658-666.	4.1	19
184	IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. American Journal of Hematology, 2019, 94, 338-345.	4.1	19
185	Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. Leukemia and Lymphoma, 2010, 51, 1233-1240.	1.3	18
186	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1609-1618.	2.5	18
187	Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL): An Analysis of a Large Cohort of Patients Treated in Routine Clinical Practice. Blood, 2015, 126, 2935-2935.	1.4	18
188	Alcohol Intake and Colorectal Cancer Risk by Molecularly Defined Subtypes in a Prospective Study of Older Women. Cancer Prevention Research, 2011, 4, 2035-2043.	1.5	17
189	Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. Haematologica, 2018, 103, 297-303.	3.5	17
190	Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways. Human Molecular Genetics, 2020, 29, 70-79.	2.9	17
191	Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal Bâ€cell lymphocytosis beyond the CLL international prognostic index. American Journal of Hematology, 2020, 95, 906-917.	4.1	17
192	The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. Haematologica, 2020, 105, 2675-2678.	3.5	17
193	Investigating the numerical effects of ascertainment bias in linkage analysis: Development of methods and preliminary results. Genetic Epidemiology, 1997, 14, 1119-1124.	1.3	16
194	Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. Blood, 2012, 120, 1687-1690.	1.4	16
195	Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts. Cytokine, 2013, 64, 523-531.	3.2	16
196	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Adult Acute Lymphocytic Leukemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute Monographs, 2014, 2014, 125-129.	2.1	16
197	The association of physical activity before and after lymphoma diagnosis with survival outcomes. American Journal of Hematology, 2018, 93, 1543-1550.	4.1	16
198	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discovery, 2021, 2, 54-69.	5.0	16

#	Article	IF	Citations
199	Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. Blood, 2021, 137, 2046-2056.	1.4	16
200	Risk of nonâ€Hodgkin lymphoma in association with germline variation in complement genes. British Journal of Haematology, 2009, 145, 614-623.	2.5	15
201	Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication. Leukemia and Lymphoma, 2015, 56, 311-314.	1.3	15
202	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. Lupus Science and Medicine, 2017, 4, e000187.	2.7	15
203	Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. Haematologica, 2018, 103, e237-e240.	3.5	15
204	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for WaldenstrÃ¶m macroglobulinemia. Nature Communications, 2018, 9, 4182.	12.8	15
205	Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. Oncologist, 2020, 25, 974-980.	3.7	15
206	Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. Leukemia and Lymphoma, 2020, 61, 2383-2388.	1.3	15
207	Development of smokeless tobaccoâ€induced oral mucosal lesions. Journal of Oral Pathology and Medicine, 1998, 27, 388-394.	2.7	14
208	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	5.0	14
209	Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia. American Journal of Hematology, 2016, 91, 776-781.	4.1	14
210	Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia. American Journal of Hematology, 2016, 91, 677-680.	4.1	14
211	Comparative analysis of de novo assemblers for variation discovery in personal genomes. Briefings in Bioinformatics, 2018, 19, 893-904.	6.5	14
212	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. Blood Cancer Journal, 2021, 11, 86.	6.2	14
213	Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes. British Journal of Haematology, 2012, 159, n/a-n/a.	2.5	13
214	Mapping of the IRF8 Gene Identifies a 3â€²UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 461-466.	2.5	13
215	Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. American Journal of Hematology, 2017, 92, 1362-1369.	4.1	13
216	A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <scp>MYC</scp>/<scp>PVT</scp>1 predicts patient outcome in two independent cohorts. British Journal of Haematology, 2018, 180, 286-290.	2.5	13

#	Article	IF	Citations
217	Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1074-1078.	2.5	13
218	Occupational insecticide exposure and risk of n<scp>onâ€Hodgkin</scp> lymphoma: A pooled c<scp>aseâ€control</scp> study from the <scp>InterLymph</scp> Consortium. International Journal of Cancer, 2021, 149, 1768-1786.	5.1	13
219	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. American Journal of Hematology, 2022, 97, 90-98.	4.1	13
220	Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota. Blood Cancer Journal, 2022, 12, 67.	6.2	13
221	Familial Chronic Lymphocytic Leukemia: What Does it Mean to Me?. Clinical Lymphoma and Myeloma, 2009, 9, S194-S197.	1.4	12
222	Increased prevalence of light chain monoclonal gammopathy of undetermined significance (<scp>LC</scp>â€<scp>MGUS</scp>) in firstâ€degree relatives of individuals with multiple myeloma. British Journal of Haematology, 2012, 157, 472-475.	2.5	12
223	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	2.9	12
224	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 2016, 11, e0160316.	2.5	12
225	Impact of metformin use on the outcomes of newly diagnosed diffuse large Bâ€cell lymphoma and follicular lymphoma. British Journal of Haematology, 2019, 186, 820-828.	2.5	12
226	Associations between Cigarette Smoking, Hormone Therapy, and Folate Intake with Incident Colorectal Cancer by TP53 Protein Expression Level in a Population-Based Cohort of Older Women. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 350-355.	2.5	11
227	Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. Haematologica, 2017, 102, e22-e25.	3.5	11
228	Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia. Blood, 2013, 121, 237-238.	1.4	10
229	Associations between Environmental Exposures and Incident Colorectal Cancer by ESR2 Protein Expression Level in a Population-Based Cohort of Older Women. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 713-719.	2.5	10
230	CORRÂ® ORS Richard A. Brand Award: Disruption in Peroxisome Proliferator-Activated Receptor-Î³ (PPARG) Increases Osteonecrosis Risk Through Genetic Variance and Pharmacologic Modulation. Clinical Orthopaedics and Related Research, 2019, 477, 1800-1812.	1.5	10
231	Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. Leukemia, 2022, 36, 119-125.	7.2	10
232	Expression of Interferon Regulatory Factor-4 (IRF4/MUM1) Is Associated with Inferior Overall Survival In Peripheral T-Cell Lymphoma. Blood, 2010, 116, 140-140.	1.4	10
233	FCGR3A/2A polymorphisms and diffuse large Bâ€cell lymphoma outcome treated with immunochemotherapy: a metaâ€analysis on 1134 patients from two prospective cohorts. Hematological Oncology, 2017, 35, 447-455.	1.7	9
234	Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy. Oncotarget, 2018, 9, 37173-37184.	1.8	9

#	Article	IF	Citations
235	Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood Cancer Journal, 2019, 9, 59.	6.2	9
236	Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. Leukemia, 2019, 33, 499-507.	7.2	9
237	Addition of venetoclax at time of progression in ibrutinibâ€treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. American Journal of Hematology, 2020, 95, E57-E60.	4.1	9
238	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). Blood, 2019, 134, 69-69.	1.4	9
239	Genetic Variation in Genes That Regulate T-Cell Differentiation and Function Is Associated with An Increased Risk of Developing B-Cell Non- Hodgkin Lymphoma. Blood, 2008, 112, 3762-3762.	1.4	9
240	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood Advances, 2022, 6, 1350-1360.	5.2	9
241	Chronic lymphocytic leukemia (CLL) with Reedâ€“Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. Blood Cancer Journal, 2022, 12, 18.	6.2	9
242	Genome-wide linkage analysis of systolic blood pressure: a comparison of two approaches to phenotype definition. BMC Genetics, 2003, 4, S13.	2.7	8
243	Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1061-1070.	2.5	8
244	Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era. Blood, 2014, 124, 1664-1664.	1.4	8
245	The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice. Blood, 2015, 126, 717-717.	1.4	8
246	FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epsteinâ€“Barr virus status. Leukemia and Lymphoma, 2013, 54, 2571-2573.	1.3	7
247	Comparison of tumor staging systems for cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. Journal of the American Academy of Dermatology, 2019, 80, 639-645.	1.2	7
248	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer Journal, 2021, 11, 47.	6.2	7
249	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. Blood, 2019, 134, 121-121.	1.4	7
250	Prevalence and Overall Survival of Low Count Monoclonal B-Cell Lymphocytosis (LC-MBL): A Screening Study of 8,297 Individuals from the Mayo Clinic Biobank. Blood, 2021, 138, 2632-2632.	1.4	7
251	A genome-wide association study of IgM antibody against phosphorylcholine: shared genetics and phenotypic relationship to chronic lymphocytic leukemia. Human Molecular Genetics, 2018, 27, 1809-1818.	2.9	6
252	Identification of factors associated with duplicate rate in ChIP-seq data. PLoS ONE, 2019, 14, e0214723.	2.5	6

#	Article	IF	Citations
253	Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci. Human Molecular Genetics, 2020, 29, 2761-2774.	2.9	6
254	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. Frontiers in Oncology, 2019, 9, 1539.	2.8	6
255	Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. Blood Cancer Journal, 2021, 11, 140.	6.2	6
256	The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States. Blood, 2018, 132, 1702-1702.	1.4	6
257	Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement. BJU International, 2011, 108, 1610-1615.	2.5	5
258	Evaluating the Influence of Quality Control Decisions and Software Algorithms on SNP Calling for the Affymetrix 6.0 SNP Array Platform. Human Heredity, 2011, 71, 221-233.	0.8	5
259	LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. Leukemia and Lymphoma, 2012, 53, 1105-1112.	1.3	5
260	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	3.3	5
261	Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy . Clinical Epidemiology, 2019, Volume 11, 987-996.	3.0	5
262	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. Npj Breast Cancer, 2020, 6, 44.	5.2	5
263	Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. American Journal of Hematology, 2021, 96, 979-988.	4.1	5
264	Autoimmune Cytopenias in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL): The Clinical Implications of Earlier Diagnosis and Longer Follow-Up.. Blood, 2006, 108, 2789-2789.	1.4	5
265	Hodgkin Transformation Of Chronic Lymphocytic Leukemia (CLL): Mayo Clinic Experience. Blood, 2013, 122, 1642-1642.	1.4	5
266	Atrial Fibrillation in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2015, 126, 2950-2950.	1.4	5
267	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. Blood, 2016, 128, 3034-3034.	1.4	5
268	Blood transfusion history and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. Cancer Causes and Control, 2019, 30, 889-900.	1.8	4
269	Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia. Journal of the American Academy of Dermatology, 2020, 83, 1581-1589.	1.2	4
270	Infectious mononucleosis, immune genotypes, and non-Hodgkin lymphoma (NHL): an InterLymph Consortium study. Cancer Causes and Control, 2020, 31, 451-462.	1.8	4

#	Article	IF	Citations
271	Aspirin and other nonsteroidal antiâ€inflammatory drugs, statins and risk of nonâ€Hodgkin lymphoma. International Journal of Cancer, 2021, 149, 535-545.	5.1	4
272	Common genetic polymorphisms contribute to the association between chronic lymphocytic leukaemia and non-melanoma skin cancer. International Journal of Epidemiology, 2021, 50, 1325-1334.	1.9	4
273	Heritable Predisposition To Richter Syndrome In Patients With Chronic Lymphocytic Leukemia. Blood, 2013, 122, 2867-2867.	1.4	4
274	Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome. Blood, 2013, 122, 4179-4179.	1.4	4
275	Disease Progression and Complications Are the Main Cause of Death in Patients with Chronic Lymphocytic Leukemia (CLL) Independent of Age and Comorbidities at Diagnosis. Blood, 2015, 126, 5265-5265.	1.4	4
276	Skin Cancers Among Chronic Lymphocytic Leukemia (CLL) Patients - the Effect of UV Radiation and CLL Clinical Characteristics. Blood, 2016, 128, 4772-4772.	1.4	4
277	Germline Variation in Complement Genes and Event-Free Survival in Follicular Lymphoma.. Blood, 2009, 114, 440-440.	1.4	4
278	B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1103-1110.	2.5	4
279	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. International Journal of Cancer, 2021, 149, 327-336.	5.1	3
280	Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia. Scientific Reports, 2021, 11, 8318.	3.3	3
281	A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Blood, 2019, 134, 4306-4306.	1.4	3
282	BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression. Blood, 2019, 134, 3050-3050.	1.4	3
283	Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database. Blood, 2019, 134, 1610-1610.	1.4	3
284	Pure Red Cell Aplasia (PRCA) in Chronic Lymphocytic Leukemia (CLL): Etiology, Therapy, and Outcomes. Blood, 2015, 126, 4169-4169.	1.4	3
285	Prevalence of Low Count (LC) Monoclonal B Cell Lymphocytosis (MBL) and Serious Infections in a Population-Based Cohort of U.S. Adults Participating in a Large Bio-Repository. Blood, 2017, 130, 831-831.	1.4	3
286	Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma. Blood, 2019, 134, 1604-1604.	1.4	3
287	Favorable Modulation of Chimeric Antigen Receptor T Cells Safety and Efficacy By the Non-Covalent BTK Inhibitor Vecabrutinib. Blood, 2021, 138, 906-906.	1.4	3
288	Inherited genetics of adult diffuse glioma and polygenic risk scoresâ€”a review. Neuro-Oncology Practice, 2022, 9, 259-270.	1.6	3

#	Article	IF	Citations
289	When the negative is positive. Blood, 2011, 117, 1441-1442.	1.4	2
290	Genetic risk of chronic lymphocytic leukemia: a tale of two cities. Leukemia and Lymphoma, 2014, 55, 735-736.	1.3	2
291	Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients. EJHaem, 2020, 1, 537-544.	1.0	2
292	Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. Human Molecular Genetics, 2021, 30, 1142-1153.	2.9	2
293	Polymorphisms in the BLyS Gene Are Associated with an Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma.. Blood, 2007, 110, 564-564.	1.4	2
294	Family-Associated Monoclonal B Lymphocytosis Is Commonly Oligoclonal and Expresses Markers Associated with Adverse Risk in CLL. Blood, 2008, 112, 3144-3144.	1.4	2
295	Statin Use and Prognosis in Patients with Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL). Blood, 2008, 112, 583-583.	1.4	2
296	Monoclonal B-Cell Lymphocytosis Is Commonly Observed Among Unaffected Members of High Risk CLL Families.. Blood, 2009, 114, 1232-1232.	1.4	2
297	Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 996-996.	1.4	2
298	Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population. Blood, 2012, 120, 1540-1540.	1.4	2
299	IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. Blood, 2013, 122, 362-362.	1.4	2
300	Hypogammaglobulinemia In Patients With Previously Untreated Chronic Lymphocytic Leukemia: Clinical Correlates and Outcomes. Blood, 2013, 122, 4178-4178.	1.4	2
301	Quality of Life at Diagnosis Independently Predicts Survival in Patients with Aggressive Lymphoma. Blood, 2014, 124, 205-205.	1.4	2
302	B-Cell Count and Survival: Differentiating Chronic Lymphocytic Leukemia (CLL) from and Monoclonal B-Cell Lymphocytosis (MBL) Based on Clinical Outcome.. Blood, 2008, 112, 2062-2062.	1.4	2
303	Whole-Exome Analysis Of DLBCL Tumors Reveals a Unique Genetic Signature Associated With Aggressive Disease. Blood, 2013, 122, 499-499.	1.4	2
304	Validation of Elevated Blood Soluble PD-L1 As an Independent Prognostic Marker in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2014, 124, 2998-2998.	1.4	2
305	The Level of Physical Activity before and after Lymphoma Diagnosis Impacts Overall and Lymphoma-Specific Survival. Blood, 2017, 130, 914-914.	1.4	2
306	The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models. Blood, 2021, 138, 2412-2412.	1.4	2

#	Article	IF	Citations
307	Differential transcriptomic profiling in ibrutinibâ€naÃ¯ve versus ibrutinibâ€resistant Richter syndrome. Hematological Oncology, 2022, 40, 302-306.	1.7	2
308	Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method. Blood Advances, 2022, 6, 3746-3750.	5.2	2
309	Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6. Blood Cancer Journal, 2022, 12, 60.	6.2	2
310	Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Myeloma Patients?. Cancer Epidemiology Biomarkers and Prevention, 0, , .	2.5	2
311	B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells. Blood Cancer Journal, 2022, 12, .	6.2	2
312	Host genetic variation in tumor necrosis factor and nuclear factorâ€ºB pathways and overall survival in mantle cell lymphoma: A discovery and replication study. American Journal of Hematology, 2019, 94, E153-E155.	4.1	1
313	The prognostic significance of <scp>del6q23</scp> in chronic lymphocytic leukemia. American Journal of Hematology, 2021, 96, E203-E206.	4.1	1
314	Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL. Blood, 2018, 132, 4204-4204.	1.4	1
315	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. Blood, 2020, 136, 39-40.	1.4	1
316	Molecular Prognostic Factors and Outcome among a Cohort of Patients with Monoclonal B-Cell Lymphocytosis (MBL).. Blood, 2007, 110, 748-748.	1.4	1
317	CD5+ Chronic B-Cell Lymphoproliferative Disorders Could Contain a Novel Disease Entity.. Blood, 2008, 112, 2065-2065.	1.4	1
318	Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource. Blood, 2012, 120, 1546-1546.	1.4	1
319	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. Blood, 2016, 128, 1104-1104.	1.4	1
320	Role of Lncrnas in Early Stage Immunoglobulin Heavy Chain Variable Region (IGHV) Unmutated CLL Disease Progression. Blood, 2016, 128, 4364-4364.	1.4	1
321	Germline Variation in Apoptosis Pathway Genes and Risk of Non-Hodgkin Lymphoma.. Blood, 2009, 114, 3933-3933.	1.4	1
322	Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. Blood, 2010, 116, 991-991.	1.4	1
323	Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. Blood, 2011, 118, 429-429.	1.4	1
324	Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL),. Blood, 2011, 118, 4152-4152.	1.4	1

#	Article	IF	Citations
325	EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (â^') Counterparts: Results From University of Iowa/Mayo Clinic SPORE. Blood, 2012, 120, 1604-1604.	1.4	1
326	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. Blood, 2013, 122, 76-76.	1.4	1
327	Transfusion History and Risk of Non-Hodgkin Lymphoma (NHL): an Interlymph Pooled Analysis. Blood, 2014, 124, 3039-3039.	1.4	1
328	Sensitivity of Ibrutinib Exposed Chronic Lymphocytic Leukemia B-Cells to Inhibition of Axl Receptor Tyrosine Kinase. Blood, 2016, 128, 2020-2020.	1.4	1
329	Liver Biopsy in Patients with Chronic Lymphocytic Leukemia: Indications and Pathological Findings. Blood, 2016, 128, 5592-5592.	1.4	1
330	Vaccination History and Risk of Lymphoma and Its Major Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0383.2021.	2.5	1
331	TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma. Blood, 2021, 138, 901-901.	1.4	1
332	Comparison of MGUS Prevalence By Race and Family History Risk Groups Using a High Sensitivity Screening Method (MASS-FIX). Blood, 2020, 136, 40-41.	1.4	1
333	Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects. Blood, 2020, 136, 30-31.	1.4	1
334	Distinct Gene Expression Signatures in Patients with Richter's Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib. Blood, 2020, 136, 30-31.	1.4	1
335	Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter's Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 16-17.	1.4	1
336	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 26-27.	1.4	1
337	Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia. Blood, 2020, 136, 49-50.	1.4	1
338	Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis. Leukemia, 2022, , .	7.2	1
339	Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia. Experimental Hematology, 2022, 111, 32-40.	0.4	1
340	Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study. Blood Cancer Journal, 2022, 12, 79.	6.2	1
341	3.12 The Prevalence of Serious Infections in a Community-Based Cohort of Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S203-S204.	0.4	0
342	3.13 Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Community-based Cohort Study of Newly Diagnosed Patients Compared to Controls. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S204-S205.	0.4	0

#	Article	IF	Citations
343	Hodgkin Transformation of Chronic Lymphocytic Leukemia (CLL): Mayo Clinic Experience. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S132-S133.	0.4	0
344	Risk factors for hypogammaglobulinemia in chronic lymphocytic leukemia patients treated with anti-CD20 monoclonal antibody-based therapies. Journal of Hematopathology, 2020, 13, 221-229.	0.4	0
345	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217.		0
346	CLL-376: Clinical Characteristics and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL), 80 Years of Age or Older. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S324-S325.	0.4	0
347	Familial Chronic Lymphocytic Leukemia(CLL): The Mayo Clinic Experience.. Blood, 2004, 104, 1906-1906.	1.4	0
348	Prior Treatment Relates More Strongly to Richterâ€™s Transformation Than ZAP-70, CD38, IgVH Gene Mutation Status, and Cytogenetic Abnormalities: Findings of an Observational Cohort Study of 962 Patients with CLL.. Blood, 2006, 108, 2777-2777.	1.4	0
349	A Large Scale Evaluation of Genetic Variation in Immune and Inflammation Genes and Risk of Non-Hodgkin Lymphoma.. Blood, 2006, 108, 817-817.	1.4	0
350	The Prognostic Significance of Cytopenia in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL).. Blood, 2007, 110, 746-746.	1.4	0
351	Statin Use and Risk of Non-Hodgkin Lymphoma (NHL): Preliminary Results from the Mayo Clinic Case-Control Study.. Blood, 2007, 110, 2615-2615.	1.4	0
352	The Physician-Patient Relationship Impacts Patient Quality of Life in Chronic Lymphocytic Leukemia: Results of an International Survey of 1482 Patients.. Blood, 2007, 110, 2060-2060.	1.4	0
353	Treatment Free Survival of Patients with MBL and Early CLL: Follow-up of 405 Patients at Mayo Clinic.. Blood, 2008, 112, 2063-2063.	1.4	0
354	Higher Intakes of Vegetables, Vitamin E, Manganese and Zinc Are Associated with a Lower Risk of Non-Hodgkin Lymphoma (NHL): Results from a Case-Control Study. Blood, 2008, 112, 3771-3771.	1.4	0
355	Influence of Age at Diagnosis On Utility of Prognostic Testing in Patients with CLL.. Blood, 2009, 114, 2342-2342.	1.4	0
356	Vitamin D Deficiency Is Associated with Inferior Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma.. Blood, 2009, 114, 1952-1952.	1.4	0
357	Melanoma and Non-Melanoma Skin Cancer in Patients with Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 1268-1268.	1.4	0
358	Family-Associated Monoclonal B Lymphocytosis Shows Differences From CLL That Suggest An Indolent Biology.. Blood, 2009, 114, 1241-1241.	1.4	0
359	Treatment of Patients with Autoimmune Cytopenia and Progressive CLL Using Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP).. Blood, 2009, 114, 4410-4410.	1.4	0
360	Monoclonal and Polyclonal Serum Free Light Chains and Clinical Outcome In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 2409-2409.	1.4	0

#	Article	IF	Citations
361	Survival of Patients with Clinically Identified Monoclonal B-Cell Lymphocytosis (MBL) Relative to the Age and Sex Matched General Population. Blood, 2010, 116, 700-700.	1.4	0
362	A BAFF-R Mutation Associated with Non-Hodgkin Lymphoma Exhibits Altered TRAF Binding and Reveals New Insights Into Proximal BAFF-R Signaling. Blood, 2010, 116, 468-468.	1.4	0
363	Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci. Blood, 2010, 116, 2443-2443.	1.4	0
364	Germline Variation in TNF and NF-Kappa B Pathways and Prognosis In Mantle Cell Lymphoma. Blood, 2010, 116, 4127-4127.	1.4	0
365	Infectious Complications In a Prospective Cohort of Community Based Newly Diagnosed Patients with Chronic Lymphocytic Leukemia (CLL).. Blood, 2010, 116, 4610-4610.	1.4	0
366	Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients,. Blood, 2011, 118, 3903-3903.	1.4	0
367	Prevalence of MBL Increases Over Time In Relatives of CLL Families,. Blood, 2011, 118, 3881-3881.	1.4	0
368	The Prevalence of Serious Infectious Complications in a Cohort of Non-Referred Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study. Blood, 2011, 118, 4610-4610.	1.4	0
369	Race As a Determinant of Disease Biology and Outcomes in Chronic Lymphocytic Leukemia. Blood, 2011, 118, 1785-1785.	1.4	0
370	Very High Risk CLL Characterized by a â€œDouble Hitâ€•Clone with Both 11q22 and 17p13 Deletion.. Blood, 2012, 120, 2486-2486.	1.4	0
371	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Blood, 2012, 120, 684-684.	1.4	0
372	Risk of Cancer in Patients with Clinical Monoclonal B-Cell Lymphocytosis (MBL): A Cohort Study of Newly Diagnosed Patients Compared to Controls.. Blood, 2012, 120, 2893-2893.	1.4	0
373	Clinical Utility of PET/CT Scanning in Patients with Chronic Lymphocytic Leukemia. Blood, 2012, 120, 3903-3903.	1.4	0
374	Chronic Lymphocytic Leukemia in Young (â‰¤ 55 years) Patients: A Comprehensive Analysis of Prognostic Factors and Outcomes.. Blood, 2012, 120, 2901-2901.	1.4	0
375	Transformation of Chronic Lymphocytic Leukemia Into Diffuse Large B-Cell Lymphoma (Richter's) Tj ETQq1 1 0.784314 rgBT /Overloc	1.4	0
376	Analysis of Stem Cell Transplant Referral in a Cohort of Newly Diagnosed Chronic Lymphocytic Leukemia Patients. Blood, 2012, 120, 4252-4252.	1.4	0
377	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. Blood, 2012, 120, 149-149.	1.4	0
378	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. Blood, 2012, 120, 1563-1563.	1.4	0

#	Article	IF	Citations
379	Host Genetics and Risk of Cardiovascular Disease in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. Blood, 2012, 120, 1573-1573.	1.4	0
380	Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies. Blood, 2012, 120, 3637-3637.	1.4	0
381	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. Blood, 2012, 120, 2702-2702.	1.4	0
382	Genomic Landscape and Clonal Heterogeneity Underlying Progression and Relapse In Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 2855-2855.	1.4	0
383	Comparison Of Single Nucleotide Mutations (SNVs) and Copy Number Variants (CNVs) Detection In Formalin Fixed Paraffin Embedded (FFPE) and Paired Frozen Tumor Tissues Using Target Capture and Sequencing Approach. Blood, 2013, 122, 1784-1784.	1.4	0
384	A Meta-Analysis Of Hodgkin Lymphoma Reveals 19p13.3 (TCF3) As a Novel Susceptibility Loc. Blood, 2013, 122, 626-626.	1.4	0
385	Racial Variations in Disease Characteristics, Presentations, Treatments, and Outcomes in Chronic Lymphocytic Leukemia (CLL). Blood, 2014, 124, 1989-1989.	1.4	0
386	Exome Sequencing in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) Families Identifies Cosegregating Functional Variants. Blood, 2014, 124, 1967-1967.	1.4	0
387	Genomic Diversity of Newly Diagnosed Follicular Lymphoma: a Pilot Investigation. Blood, 2014, 124, 1691-1691.	1.4	0
388	Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 131-131.	1.4	0
389	Correlation Between Peripheral Blood Counts and Extent of Bone Marrow Infiltration in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 2926-2926.	1.4	0
390	Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma. Blood, 2015, 126, 1501-1501.	1.4	0
391	Mutations in Driver Genes and Changes in Clonal Dynamics Are Associated with Shorter Time to Treatment in MBL Cases. Blood, 2015, 126, 5264-5264.	1.4	0
392	Risk of Monoclonal Gammopathy of Undetermined Significance in First-Degree Relatives of Multiple Myeloma Cases By Cytogenetic Subtype. Blood, 2016, 128, 4425-4425.	1.4	0
393	Liver Dysfunction in Previously Untreated Chronic Lymphocytic Leukemia: Prevalence and Outcomes in a Large Cohort. Blood, 2016, 128, 5585-5585.	1.4	0
394	The Role of Splenectomy in the Care and Treatment of the CLL Patient. Blood, 2016, 128, 5575-5575.	1.4	0
395	No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era. Blood, 2016, 128, 107-107.	1.4	0
396	Clinically Ascertained Monoclonal B-Cell Lymphocytosis: Risk of Progression to Chronic Lymphocytic Leukemia Requiring Therapy and Outcomes. Blood, 2016, 128, 3228-3228.	1.4	0

#	Article	IF	Citations
397	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 2935-2935.	1.4	0
398	Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL). Blood, 2018, 132, 3116-3116.	1.4	0
399	Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation. Blood, 2018, 132, 1857-1857.	1.4	0
400	Large-Scale Linkage Analysis of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS) Families. Blood, 2018, 132, 4501-4501.	1.4	0
401	Clinical and Quality of Life Predictors of Failure to Achieve Event Free Survival at 24 Months in Patients Aged 70 Years and Older with Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 3579-3579.	1.4	0
402	Association between the Risk of Low/High-Count Monoclonal B-Cell Lymphocytosis (MBL) and the Chronic Lymphocytic Leukemia (CLL) Polygenic Risk Score (PRS). Blood, 2018, 132, 5538-5538.	1.4	0
403	Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era. Blood, 2018, 132, 4140-4140.	1.4	0
404	Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis. Blood, 2019, 134, 3022-3022.	1.4	0
405	Association between a Polygenic Risk Score for Multiple Myeloma Risk and Overall Survival. Blood, 2019, 134, 4366-4366.	1.4	0
406	Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients. Blood, 2019, 134, 5215-5215.	1.4	0
407	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Blood, 2019, 134, 919-919.	1.4	0
408	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. Blood, 2019, 134, 923-923.	1.4	0
409	Germline Variation Predicts Treatment Response in Multiple Myeloma. Blood, 2019, 134, 4397-4397.	1.4	0
410	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. Blood, 2019, 134, 1480-1480.	1.4	0
411	Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era. Blood, 2019, 134, 422-422.	1.4	0
412	Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL). Blood, 2019, 134, 852-852.	1.4	0
413	The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis. Blood, 2019, 134, 3037-3037.	1.4	0
414	Genome-Wide Association Study Identifies an Immune-Related Etiology for Severe Aplastic Anemia. Blood, 2019, 134, 1224-1224.	1.4	0

#	Article	IF	Citations
415	Utilization of a Targeted Next Generation Sequencing Assay to Identify Copy Number Alterations in Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis. Blood, 2021, 138, 4677-4677.	1.4	0
416	Optimized Inhibition of GM-CSF in Preclinical Models of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Blood, 2021, 138, 2777-2777.	1.4	0
417	Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) after Progression on I Alone (V-naÃ¯ve) or after Progression on Sequential I and V (Double-Refractory). Blood, 2021, 138, 1560-1560.	1.4	0
418	Relationship and Susceptibility to Serious Infections Among Monoclonal B-Cell Lymphocytosis (MBL), Monoclonal Gammopathy of Undetermined Significance (MGUS), and Clonal Hematopoiesis (CH) Premalignant Conditions. Blood, 2021, 138, 3739-3739.	1.4	0
419	B Cell Receptor Signaling Drives APOBEC3 Expression Via Direct Enhancer Regulation in Chronic Lymphocytic Leukemia B Cells. Blood, 2021, 138, 3313-3313.	1.4	0
420	TP53 Aberrations and Outcomes in MBL and Untreated CLL. Blood, 2021, 138, 2618-2618.	1.4	0
421	Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes. Blood, 2020, 136, 35-36.	1.4	0
422	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older. Blood, 2020, 136, 26-27.	1.4	0
423	Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma. Blood, 2020, 136, 10-12.	1.4	0
424	Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models. Blood, 2020, 136, 28-29.	1.4	0
425	Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia. Blood, 2020, 136, 12-13.	1.4	0
426	Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia. Blood, 2020, 136, 1-1.	1.4	0
427	Body Mass Index and Clinical Factors Associated with Monoclonal Gammopathy of Undetermined Significance (MGUS) Progression in Olmsted County, Minnesota. Blood, 2020, 136, 15-16.	1.4	0
428	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. Blood, 2020, 136, 17-18.	1.4	0
429	Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study. Blood, 2020, 136, 7-8.	1.4	0
430	The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models. Transplantation and Cellular Therapy, 2022, 28, S163-S164.	1.2	0